Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis Delta International Network (HDIN), Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J. Gane, Robert G. Gish, Jeffrey S. Glenn, S. Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer

Research output: Contribution to journalReview article

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

Original languageEnglish
Pages (from-to)1008-1015
Number of pages8
JournalJournal of Hepatology
Volume70
Issue number5
DOIs
Publication statusPublished - May 1 2019

    Fingerprint

Keywords

  • Hepatitis D
  • New treatment approaches
  • Surrogate marker
  • Treatment endpoints

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis Delta International Network (HDIN), Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., Gane, E. J., Gish, R. G., Glenn, J. S., Hamid, S., Heller, T., Koh, C., Lampertico, P., Lurie, Y., Manns, M., Parana, R., Rizzetto, M., Urban, S., & Wedemeyer, H. (2019). Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. Journal of Hepatology, 70(5), 1008-1015. https://doi.org/10.1016/j.jhep.2018.12.022